SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 209 filers reported holding SAGE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,960,832 | -56.6% | 629,778 | -0.9% | 0.00% | -50.0% |
| Q2 2023 | $29,871,947 | +19.6% | 635,303 | +6.7% | 0.01% | +20.0% |
| Q1 2023 | $24,984,328 | +8.1% | 595,432 | -1.7% | 0.01% | 0.0% |
| Q4 2022 | $23,106,165 | -2.7% | 605,825 | -0.1% | 0.01% | 0.0% |
| Q3 2022 | $23,739,000 | +21.7% | 606,216 | +0.4% | 0.01% | +25.0% |
| Q2 2022 | $19,508,000 | +124.6% | 603,959 | +130.1% | 0.00% | +100.0% |
| Q1 2022 | $8,686,000 | -24.5% | 262,434 | -2.9% | 0.00% | 0.0% |
| Q4 2021 | $11,500,000 | -3.5% | 270,313 | +0.5% | 0.00% | 0.0% |
| Q3 2021 | $11,919,000 | -23.6% | 269,006 | -2.0% | 0.00% | -33.3% |
| Q2 2021 | $15,600,000 | -25.3% | 274,601 | -1.6% | 0.00% | -25.0% |
| Q1 2021 | $20,890,000 | -17.3% | 279,090 | -4.4% | 0.00% | -20.0% |
| Q4 2020 | $25,247,000 | +38.0% | 291,830 | -2.5% | 0.01% | +25.0% |
| Q3 2020 | $18,301,000 | +44.1% | 299,437 | -2.0% | 0.00% | +33.3% |
| Q2 2020 | $12,699,000 | +68.3% | 305,422 | +16.2% | 0.00% | +50.0% |
| Q1 2020 | $7,547,000 | -58.4% | 262,770 | +4.6% | 0.00% | -50.0% |
| Q4 2019 | $18,128,000 | -54.5% | 251,127 | -11.6% | 0.00% | -60.0% |
| Q3 2019 | $39,855,000 | -20.7% | 284,088 | +3.4% | 0.01% | -16.7% |
| Q2 2019 | $50,280,000 | +21.8% | 274,620 | +5.8% | 0.01% | +20.0% |
| Q1 2019 | $41,275,000 | +95.7% | 259,501 | +17.9% | 0.01% | +66.7% |
| Q4 2018 | $21,090,000 | -32.2% | 220,176 | -0.1% | 0.01% | -25.0% |
| Q3 2018 | $31,125,000 | -10.4% | 220,349 | -0.7% | 0.01% | -11.1% |
| Q2 2018 | $34,746,000 | -56.3% | 221,976 | -55.0% | 0.01% | -57.1% |
| Q1 2018 | $79,503,000 | +8.7% | 493,595 | +11.1% | 0.02% | +10.5% |
| Q4 2017 | $73,157,000 | +184.9% | 444,158 | +7.8% | 0.02% | +171.4% |
| Q3 2017 | $25,678,000 | -21.6% | 412,174 | +0.2% | 0.01% | -22.2% |
| Q2 2017 | $32,767,000 | +32.1% | 411,444 | +17.9% | 0.01% | +28.6% |
| Q1 2017 | $24,802,000 | +42.2% | 348,970 | +2.2% | 0.01% | +40.0% |
| Q4 2016 | $17,439,000 | +23.8% | 341,534 | +11.6% | 0.01% | +25.0% |
| Q3 2016 | $14,091,000 | +64.8% | 305,998 | +7.8% | 0.00% | +33.3% |
| Q2 2016 | $8,550,000 | +46.4% | 283,797 | +55.7% | 0.00% | +50.0% |
| Q1 2016 | $5,842,000 | -33.9% | 182,223 | +20.1% | 0.00% | -33.3% |
| Q4 2015 | $8,843,000 | +43.8% | 151,685 | +4.4% | 0.00% | +50.0% |
| Q3 2015 | $6,148,000 | +3.5% | 145,271 | +78.6% | 0.00% | 0.0% |
| Q2 2015 | $5,939,000 | +92.0% | 81,343 | +32.1% | 0.00% | +100.0% |
| Q1 2015 | $3,093,000 | +44.1% | 61,594 | +5.1% | 0.00% | 0.0% |
| Q4 2014 | $2,146,000 | +388.8% | 58,615 | +321.4% | 0.00% | – |
| Q3 2014 | $439,000 | – | 13,911 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |